{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T08:28:43Z","timestamp":1649147323771},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,11,26]],"date-time":"2012-11-26T00:00:00Z","timestamp":1353888000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/2162-3619-1-35","type":"journal-article","created":{"date-parts":[[2012,11,26]],"date-time":"2012-11-26T19:16:14Z","timestamp":1353957374000},"source":"Crossref","is-referenced-by-count":4,"title":["Impact of tandem autologous stem cell transplantation and response to transplant in the outcome of multiple myeloma"],"prefix":"10.1186","volume":"1","author":[{"given":"Rui","family":"Bergantim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda","family":"Trigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 E","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,11,26]]},"reference":[{"issue":"11","key":"38_CR1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K: Multiple myeloma. N Eng J Med 2011,364(11):1046\u20131060. 10.1056\/NEJMra1011442","journal-title":"N Eng J Med"},{"issue":"6","key":"38_CR2","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","volume":"111","author":"R Kyle","year":"2008","unstructured":"Kyle R, Rajkumar SV: Multiple myeloma. Blood 2008,111(6):2962\u20132972. 10.1182\/blood-2007-10-078022","journal-title":"Blood"},{"issue":"15","key":"38_CR3","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1200\/JCO.2006.09.0100","volume":"25","author":"SY Kristinsson","year":"2007","unstructured":"Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bjorkholm M: Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007,25(15):1993\u20131999. 10.1200\/JCO.2006.09.0100","journal-title":"J Clin Oncol"},{"issue":"3","key":"38_CR4","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BG Durie","year":"1975","unstructured":"Durie BG, Salmon SE: The clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975,36(3):842\u2013854. 10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","journal-title":"Cancer"},{"issue":"15","key":"38_CR5","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BGM, et al.: INTERNATIONAL al staging system for multiple myeloma. J Clin Oncol 2005,23(15):3412\u20133420. 10.1200\/JCO.2005.04.242","journal-title":"J Clin Oncol"},{"issue":"14","key":"38_CR6","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1200\/JCO.2010.32.8435","volume":"29","author":"AL Herv\u00e9","year":"2011","unstructured":"Herv\u00e9 AL, Florence M, Philippe M, et al.: Molecular heterogeneity of multiple myeloma: pathogenesis is, prognosis, and therapeutic Implications. J Clin Oncol 2011,29(14):1893\u20131897. 10.1200\/JCO.2010.32.8435","journal-title":"J Clin Oncol"},{"issue":"18","key":"38_CR7","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1056\/NEJMra041875","volume":"351","author":"RA Kyle","year":"2004","unstructured":"Kyle RA: a. Multiple myeloma. N Eng J Med 2004,351(18):1860\u20131873. 10.1056\/NEJMra041875","journal-title":"N Eng J Med"},{"issue":"14","key":"38_CR8","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1200\/JCO.2010.34.0760","volume":"29","author":"Ma CS","year":"2011","unstructured":"CS Ma, Davies FE, Laubach JP, et al.: Future directions of next-generation novel Therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol 2011,29(14):1916\u20131923. 10.1200\/JCO.2010.34.0760","journal-title":"J Clin Oncol"},{"issue":"7","key":"38_CR9","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1200\/JCO.2009.25.6081","volume":"28","author":"B Barlogie","year":"2010","unstructured":"Barlogie B, Attal M, Crowley J, et al.: Long-term follow-up trials of autotransplantation for multiple myeloma: update of the intergroup protocols Conducted by francophone du myeloma, Southwest Oncology Group, and University of Arkansas for Medical Sciences. J Clin Oncol 2010,28(7):1209\u20131214. 10.1200\/JCO.2009.25.6081","journal-title":"J Clin Oncol"},{"issue":"10","key":"38_CR10","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.4065\/83.10.1131","volume":"83","author":"Ma Gertz","year":"2008","unstructured":"Gertz Ma, Ansell SM, Dingli D, et al.: Autologous Stem Cell Transplant in 716 Patients With Multiple Myeloma: Low Treatment-Related Mortality, Feasibility of Outpatient Transplant, and Effect of a Multidisciplinary Quality Initiative. Mayo Clin Proc 2008,83(10):1131\u20131135. 10.4065\/83.10.1131","journal-title":"Mayo Clin Proc"},{"issue":"25","key":"38_CR11","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1056\/NEJMct0805626","volume":"360","author":"JL Harousseau","year":"2009","unstructured":"Harousseau JL, Moreau P: Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Eng J Med 2009,360(25):2645\u20132654. 10.1056\/NEJMct0805626","journal-title":"N Eng J Med"},{"issue":"2","key":"38_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa M, et al.: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroup Fran\u00e7ais du Myeloma. N Eng J Med 1996,335(2):91\u201397. 10.1056\/NEJM199607113350204","journal-title":"N Eng J Med"},{"issue":"4","key":"38_CR13","first-page":"893","volume":"18","author":"M Hussein","year":"2004","unstructured":"Hussein M: Role of high-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. J Clin Oncol 2004,18(4):893.","journal-title":"J Clin Oncol"},{"issue":"23","key":"38_CR14","doi-asserted-by":"publisher","first-page":"6063","DOI":"10.1182\/blood-2011-02-297325","volume":"117","author":"M Cavo","year":"2011","unstructured":"Cavo M, Rajkumar SV, Palumbo A, et al.: International Myeloma Working Group (IMWG) consensus approach to the Treatment of Multiple Myeloma Patients who are candidates for autologous stem-cell transplantation. Blood 2011,117(23):6063\u20136073. 10.1182\/blood-2011-02-297325","journal-title":"Blood"},{"issue":"11","key":"38_CR15","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.3109\/10428194.2010.516378","volume":"51","author":"M Engelhardt","year":"2010","unstructured":"Engelhardt M, Udi J, Kleber M, et al.: European Myeloma Network: The 3rd Trialist Forum Consensus Statement from the European expert meeting on multiple myeloma. Leuk Lymphoma 2010,51(11):2006\u20132011. 10.3109\/10428194.2010.516378","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"38_CR16","doi-asserted-by":"publisher","first-page":"3968","DOI":"10.1182\/blood-2007-10-117457","volume":"111","author":"A Palumbo","year":"2008","unstructured":"Palumbo A, Facon T, Sonneveld P, et al.: Thalidomide for Treatment of multiple myeloma: 10 years later. Blood 2008,111(8):3968\u20133977. 10.1182\/blood-2007-10-117457","journal-title":"Blood"},{"issue":"9","key":"38_CR17","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF, Schlag R, Khuageva NK, et al.: Bortezomib plus melphalan and prednisone for initial Treatment of multiple myeloma. N Eng J Med 2008,359(9):906\u2013917. 10.1056\/NEJMoa0801479","journal-title":"N Eng J Med"},{"issue":"6","key":"38_CR18","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/j.1365-2141.2005.05540.x","volume":"129","author":"S Jagannath","year":"2005","unstructured":"Jagannath S, Durie BGM, Wolf J, et al.: Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005,129(6):776\u2013783. 10.1111\/j.1365-2141.2005.05540.x","journal-title":"Br J Haematol"},{"key":"38_CR19","first-page":"1498","volume":"91","author":"JL Harousseau","year":"2006","unstructured":"Harousseau JL, Attal M, Stoppa A-m, Renaud M, Huriez CH: Bortezomib plus dexamethasone the induction Treatment prior to autologous stem cell transplantation in Patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006, 91: 1498\u20131505.","journal-title":"Haematologica"},{"issue":"21","key":"38_CR20","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"M Dimopoulos","year":"2007","unstructured":"Dimopoulos M, Spencer A, Attal M, et al.: Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Eng J Med 2007,357(21):2123\u20132132. 10.1056\/NEJMoa070594","journal-title":"N Eng J Med"},{"issue":"2","key":"38_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.blre.2008.07.003","volume":"23","author":"A Palumbo","year":"2009","unstructured":"Palumbo A, Dimopoulos M, San Miguel J, et al.: Lenalidomide in combination with dexamethasone for the Treatment of relapsed or refractory multiple myeloma. Blood Rev 2009,23(2):87\u201393. 10.1016\/j.blre.2008.07.003","journal-title":"Blood Rev"},{"issue":"5","key":"38_CR22","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, et al.: Improved survival in multiple myeloma and the Impact of Novel Therapies. Blood 2008,111(5):2516\u20132520. 10.1182\/blood-2007-10-116129","journal-title":"Blood"},{"issue":"12","key":"38_CR23","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1038\/leu.2009.179","volume":"23","author":"JP Laubach","year":"2009","unstructured":"Laubach JP, Mitsiades CS, the Mahindra, et al.: The use of novel agents in the Treatment of relapsed and refractory multiple myeloma. Leukemia 2009,23(12):2222\u20132232. 10.1038\/leu.2009.179","journal-title":"Leukemia"},{"issue":"3","key":"38_CR24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.blre.2010.03.001","volume":"24","author":"D Dingli","year":"2010","unstructured":"Dingli D, Rajkumar SV: How best to use new Therapies in multiple myeloma. Blood Rev 2010,24(3):91\u2013100. 10.1016\/j.blre.2010.03.001","journal-title":"Blood Rev"},{"issue":"6","key":"38_CR25","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, et al.: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982,5(6):649\u2013655. 10.1097\/00000421-198212000-00014","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"38_CR26","first-page":"691","volume":"17","author":"H Goldschmidt","year":"1996","unstructured":"Goldschmidt H, Hegenbart U, Haas R, Hunstein W: Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g\/m2) and granulocyte colony-stimulating factor in Patients with multiple myeloma. Bone Marrow Transplant 1996,17(5):691\u2013697.","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"38_CR27","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/bmt.2008.369","volume":"43","author":"M Gertz","year":"2010","unstructured":"Gertz M, Kumar S, Lacy MQ, et al.: Comparison of high-dose CY with growth factor and growth factor alone for mobilization of stem cells for transplantation in Patients with multiple myeloma. Bone Marrow Transplant 2010,43(8):619\u2013625.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"38_CR28","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"P Moreau","year":"2002","unstructured":"Moreau P: Comparison of 200 mg\/m2 melphalan and 8 Gy total body irradiation plus 140 mg\/m2 melphalan conditioning regimens for the peripheral blood stem cell transplantation in Patients with newly diagnosed multiple myeloma: final analysis of the Intergroup Francop. Blood 2002,99(3):731\u2013735. 10.1182\/blood.V99.3.731","journal-title":"Blood"},{"issue":"9","key":"38_CR29","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BGM Durie","year":"2006","unstructured":"Durie BGM, Harousseau JL, Miguel JS, et al.: International uniform response criteria for multiple myeloma. Leukemia 2006,20(9):1467\u20131473. 10.1038\/sj.leu.2404284","journal-title":"Leukemia"},{"key":"38_CR30","unstructured":"Services of UD HAH: Terminology Common Criteria for Adverse Events (CTCAE).2010; 2009. Available at: http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/About.html"},{"issue":"1","key":"38_CR31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1182\/blood-2005-06-2573","volume":"107","author":"P Moreau","year":"2006","unstructured":"Moreau P, Hullin C, Garban F, et al.: Tandem autologous stem cell transplantation in high-risk new multiple myeloma: final results of the prospective and randomized IFM 99\u201304 protocol. Blood 2006,107(1):397\u2013403. 10.1182\/blood-2005-06-2573","journal-title":"Blood"},{"issue":"15","key":"38_CR32","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1182\/blood-2009-03-201053","volume":"114","author":"JL Harousseau","year":"2009","unstructured":"Harousseau JL, Attal M, Avet-Loiseau H: The role of complete response in multiple myeloma. Blood 2009,114(15):3139\u20133146. 10.1182\/blood-2009-03-201053","journal-title":"Blood"},{"issue":"10","key":"38_CR33","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.3324\/haematol.11534","volume":"92","author":"HJK Van de Velde","year":"2007","unstructured":"Van de Velde HJK, Liu X, Chen G, et al.: Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007,92(10):1399\u20131406. 10.3324\/haematol.11534","journal-title":"Haematologica"},{"issue":"35","key":"38_CR34","doi-asserted-by":"publisher","first-page":"5775","DOI":"10.1200\/JCO.2008.17.9721","volume":"26","author":"JJ Lahuerta","year":"2008","unstructured":"Lahuerta JJ, Mateos MV, Mart\u00ednez-L\u00f3pez J, et al.: Influence of pre-and post-transplantation outcome of responses on Patients with multiple myeloma: response of sequential improvement and achievement of complete response are Associated with longer survival. J Clin Oncol 2008,26(35):5775\u20135782. 10.1200\/JCO.2008.17.9721","journal-title":"J Clin Oncol"},{"issue":"15","key":"38_CR35","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1200\/JCO.2009.25.4250","volume":"28","author":"AA Chanan-Khan","year":"2010","unstructured":"Chanan-Khan AA, Giralt S: Importance of Achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 2010,28(15):2612\u20132624. 10.1200\/JCO.2009.25.4250","journal-title":"J Clin Oncol"},{"key":"38_CR36","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1182\/blood-2011-01-332320","volume":"118","author":"J Martinez-Lopez","year":"2011","unstructured":"Martinez-Lopez J, Blade J, Mateos MV, et al.: Long-term Prognostic Significance of response in multiple myeloma after stem cell transplantation. Blood 2011, 118: 529\u2013534. 10.1182\/blood-2011-01-332320","journal-title":"Blood"},{"issue":"12","key":"38_CR37","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1182\/blood-2011-06-297853","volume":"118","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Gahrton G, Bergsagel PL: Approach to the Treatment of multiple myeloma: a clash of philosophies. Blood 2011,118(12):3205\u20133211. 10.1182\/blood-2011-06-297853","journal-title":"Blood"},{"issue":"23","key":"38_CR38","doi-asserted-by":"publisher","first-page":"7073","DOI":"10.1158\/1078-0432.CCR-07-0527","volume":"13","author":"J Haessler","year":"2007","unstructured":"Haessler J, Shaughnessy JD, Zhan F, et al.: Benefit of complete response in multiple myeloma limited to high-risk Subgroup Identified by gene expression profiling. Clin Cancer Res 2007,13(23):7073\u20137079. 10.1158\/1078-0432.CCR-07-0527","journal-title":"Clin Cancer Res"},{"issue":"7","key":"38_CR39","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/bmt.2010.233","volume":"46","author":"MA Gertz","year":"2011","unstructured":"Gertz MA, Gastineau DA, Lacy MQ, et al.: Without SCT in multiple myeloma growth factor: engraftment kinetics, hospitalization and bacteremia. Bone Marrow Transplant 2011,46(7):956\u2013961. 10.1038\/bmt.2010.233","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"38_CR40","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V93.1.55","volume":"93","author":"B Barlogie","year":"1999","unstructured":"Barlogie B, Jagannath S, Desikan KR, et al.: Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999,93(1):55\u201365.","journal-title":"Blood"},{"issue":"17","key":"38_CR41","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1200\/JCO.2006.10.2509","volume":"25","author":"M Cavo","year":"2007","unstructured":"Cavo M, Tosi P, Zamagni E, et al.: Prospective, randomized study of single Compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007,25(17):2434\u20132441. 10.1200\/JCO.2006.10.2509","journal-title":"J Clin Oncol"},{"issue":"7","key":"38_CR42","doi-asserted-by":"publisher","first-page":"928","DOI":"10.3324\/haematol.11168","volume":"92","author":"P Sonneveld","year":"2007","unstructured":"Sonneveld P, van der Holt B, Segeren CM, et al.: Intermediate-dose melphalan myeloablative Compared with Treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group trial HOVON 24. Haematologica 2007,92(7):928\u2013935. 10.3324\/haematol.11168","journal-title":"Haematologica"},{"issue":"26","key":"38_CR43","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa032290","volume":"349","author":"M Attal","year":"2003","unstructured":"Attal M, Harousseau JL, Facon T, et al.: Single versus double autologous stem-cell transplantation for multiple myeloma. N Eng J Med 2003,349(26):2495\u20132502. 10.1056\/NEJMoa032290","journal-title":"N Eng J Med"},{"issue":"14","key":"38_CR44","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1200\/JCO.2010.32.5878","volume":"29","author":"P Moreau","year":"2011","unstructured":"Moreau P, Avet-Loiseau H, Harousseau JL, Attal M: Current trends in autologous stem-cell transplantation for myeloma in the era of Novel Therapies. J Clin Oncol 2011,29(14):1898\u20131906. 10.1200\/JCO.2010.32.5878","journal-title":"J Clin Oncol"},{"issue":"10","key":"38_CR45","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.4065\/83.10.1142","volume":"83","author":"SV Rajkumar","year":"2008","unstructured":"Rajkumar SV: Treatment of myeloma: cure vs control. Mayo Clin Proc 2008,83(10):1142\u20131145. 10.4065\/83.10.1142","journal-title":"Mayo Clin Proc"},{"key":"38_CR46","volume-title":"Biol Blood Marrow Transplant","author":"N Kroger","year":"2012","unstructured":"Kroger N, Badbaran A, Zabelina T, et al.: Impact of high risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2012, \u2009. [Epub ahead of print] 10.1016\/j.bbmt.2012.10.008"},{"issue":"22","key":"38_CR47","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1200\/JCO.2010.32.7312","volume":"29","author":"B Bjorkstrand","year":"2011","unstructured":"Bjorkstrand B, Iacobelli S, Hegenbart U, et al.: Tandem autologous\/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol 2011,29(22):3016\u20133022. 10.1200\/JCO.2010.32.7312","journal-title":"J Clin Oncol"},{"key":"38_CR48","volume-title":"Bone Marrow Transplant","author":"KE Armenson","year":"2012","unstructured":"Armenson KE, Hill EG, Costa LJ: Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment. Bone Marrow Transplant 2012, \u2009. Epub ahead of print 10.1038\/bmt.2012.173"},{"issue":"13","key":"38_CR49","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(11)70243-1","volume":"12","author":"A Krishnan","year":"2011","unstructured":"Krishnan A, Pasquini MC, Logan B, et al.: Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011,12(13):1195\u20131203. 10.1016\/S1470-2045(11)70243-1","journal-title":"Lancet Oncol"},{"issue":"5","key":"38_CR50","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","volume":"116","author":"PG Richardson","year":"2010","unstructured":"Richardson PG, Weller E, Lonial S, et al.: Lenalidomide, bortezomib, and dexamethasone combination therapy in Patients with newly diagnosed multiple myeloma. Blood 2010,116(5):679\u2013686. 10.1182\/blood-2010-02-268862","journal-title":"Blood"},{"issue":"3","key":"38_CR51","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood-2011-02-334755","volume":"118","author":"AJ Jakubowiak","year":"2011","unstructured":"Jakubowiak AJ, Griffith K, Reece DE, et al.: Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1 \/2 Multiple Myeloma Research Consortium trial. Blood 2011,118(3):535\u2013543. 10.1182\/blood-2011-02-334755","journal-title":"Blood"},{"issue":"7","key":"38_CR52","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/leu.2010.116","volume":"24","author":"S Kumar","year":"2011","unstructured":"Kumar S, Flinn IW, Noga S, Rifkin R, Rajkumar S: Bortezomib, dexamethasone, and cyclophosphamide combination lenalidomide for newly diagnosed multiple myeloma: phase 1 results from the multicenter study EVOLUTION. Leukemia 2011,24(7):1350\u20131356.","journal-title":"Leukemia"},{"key":"38_CR53","unstructured":"MFI \/DFCI. TRIAL DFCI003 \/10\u2013050: A Randomized Phase III Study Comparing Conventional Dose Combination of Treatment Using The lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma. Available at: http:\/\/www.ifm-dfci.org\/"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2162-3619-1-35.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/2162-3619-1-35\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2162-3619-1-35.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T00:24:41Z","timestamp":1594945481000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/2162-3619-1-35"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,26]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["38"],"URL":"https:\/\/doi.org\/10.1186\/2162-3619-1-35","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,26]]},"article-number":"35"}}